Clinical utility of sputum cytology in severe asthma: insights from a specialist centre

<title>Extract</title> Severe asthma is a heterogeneous condition requiring multifaceted management. Inhaled corticosteroids (ICS) remain the cornerstone of treatment; however, some patients remain uncontrolled or exhibit ICS resistance, necessitating biologic therapy. While biologics primarily target type 2 (T₂)-driven inflammation, some exhibit non-T₂, often neutrophilic, airway inflammation [1]. Accurate assessment of airway inflammation is crucial for precision medicine and phenotype-based treatment in severe asthma [1, 2].